LVTX Key Statistics, Chart & Performance
The current stock price of LVTX is 1.74 USD. In the past month the price increased by 8.07%. In the past year, price increased by 8.75%.
LVTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.27 | 405.28B | ||
| AMGN | AMGEN INC | 14.98 | 176.43B | ||
| GILD | GILEAD SCIENCES INC | 14.85 | 150.87B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.59B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 784.65 | 52.87B | ||
| INSM | INSMED INC | N/A | 37.77B | ||
| NTRA | NATERA INC | N/A | 31.58B | ||
| BIIB | BIOGEN INC | 10.62 | 26.09B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.82 | 21.39B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About LVTX
Company Profile
LAVA Therapeutics NV is an immuno-oncology company, which engages in the proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid tumors and hematological malignancies. The company is headquartered in Utrecht, Utrecht and currently employs 34 full-time employees. The company went IPO on 2021-03-25. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
Company Info
LAVA Therapeutics NV
Yalelaan 60
Utrecht UTRECHT NL
Employees: 34
Phone: 31630003035
LAVA Therapeutics NV / LVTX FAQ
What does LVTX do?
LAVA Therapeutics NV is an immuno-oncology company, which engages in the proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid tumors and hematological malignancies. The company is headquartered in Utrecht, Utrecht and currently employs 34 full-time employees. The company went IPO on 2021-03-25. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
Can you provide the latest stock price for LAVA Therapeutics NV?
The current stock price of LVTX is 1.74 USD. The price decreased by -3.87% in the last trading session.
Does LAVA Therapeutics NV pay dividends?
LVTX does not pay a dividend.
How is the ChartMill rating for LAVA Therapeutics NV?
LVTX has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is LAVA Therapeutics NV (LVTX) stock traded?
LVTX stock is listed on the Nasdaq exchange.
Can you provide the sector and industry classification for LAVA Therapeutics NV?
LAVA Therapeutics NV (LVTX) operates in the Health Care sector and the Biotechnology industry.
LVTX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to LVTX. When comparing the yearly performance of all stocks, LVTX is one of the better performing stocks in the market, outperforming 75.73% of all stocks.
LVTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LVTX. The financial health of LVTX is average, but there are quite some concerns on its profitability.
LVTX Financial Highlights
Over the last trailing twelve months LVTX reported a non-GAAP Earnings per Share(EPS) of -0.86. The EPS increased by 16.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -69.12% | ||
| ROE | -190.76% | ||
| Debt/Equity | 0 |
LVTX Forecast & Estimates
7 analysts have analysed LVTX and the average price target is 1.4 USD. This implies a price decrease of -19.69% is expected in the next year compared to the current price of 1.74.
For the next year, analysts expect an EPS growth of 7.87% and a revenue growth -100% for LVTX